The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Antimicrobial Dosing Considerations in Obese Adult Patients: Insights from the Society of Infectious Diseases Pharmacists
Abstract
As obesity continues to increase in prevalence throughout the world, it becomes important to explore the effects that obesity has on antimicrobial disposition. Physiologic changes in obesity can alter both the volume of distribution and clearance of many commonly used antimicrobials. These changes often present challenges such as estimation of creatinine clearance to predict drug clearance. Although these physiologic changes are increasingly being characterized, few studies assessing alterations in tissue drug distribution and the effects of obesity on antimicrobial pharmacokinetics have been published. The available data are most plentiful for antibiotics that historically have included clinical therapeutic drug monitoring. These data suggest that dosing of vancomycin and aminoglycosides be based on total body weight and adjusted body weight, respectively. Obese patients may require larger doses of β‐lactams to achieve similar concentrations as those of patients who are not obese. Fluoroquinolone pharmacokinetics are variably altered by obesity, which prevents a uniform approach. Data on the pharmacokinetics of drugs that have activity against gram‐positive organisms— quinupristin‐dalfopristin, linezolid, and daptomycin—reveal that they are altered in the presence of obesity, but more data are needed to solidify dosing recommendations. Limited data are available on nonantibacterials. An understanding of the physiologic changes in obesity and the available literature on specific antibiotics is valuable in providing a framework for rational selection of dosages in this increasingly common population of obese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
(2000) · PubMed · Cited by 13,173
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Adipose tissue, adipokines, and inflammation
Fantuzzi, G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.02.023 · Cited by 2,606 · cited 2×
“Adipose tissue is viewed as an active secretory organ that produces the adipokines leptin and adiponectin, which play an active role in inflammatory and immune-mediated cellsignaling pathways.(6) However, the specific role of these adipokines as well as cytokines associated with adiposity such as interleukin-6 and tum…”
BackgroundEpidemic obesity and type 2 diabetes in Asia
Yoon, K.-H., Lee, J.-H., Kim, J.-W., Cho, J. H., Choi, Y.-H., Ko, S.-H., Zimmet, P., & Son, H.-Y. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69703-1 · Cited by 1,580
Falagas, M. E., & Kompoti, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70523-0 · Cited by 811
Verhave, J. C., Fesler, P., Ribstein, J., du Cailar, G., & Mimran, A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.05.011 · Cited by 386
The Origin of the “Ideal” Body Weight Equations
Pai, M. P., & Paloucek, F. P. (2000) · The Annals of Pharmacotherapy · doi:10.1345/1542-6270(2000)034<1066:tootbw>2.0.co;2 · Cited by 380
Self-citationPostoperative Complications in Obese and Nonobese Patients
Bamgbade, O. A., Rutter, T. W., Nafiu, O. O., & Dorje, P. (2007) · World Journal of Surgery · doi:10.1007/s00268-006-0305-0 · Cited by 365
What is the best size descriptor to use for pharmacokinetic studies in the obese?
Green, B., & Duffull, S. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02157.x · Cited by 353
Salazar, D. E., & Corcoran, G. B. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90310-5 · Cited by 252
Antibiotic prophylaxis for surgery in morbidly obese patients.
Forse, R. A., Karam, B. S., MacLean, L. D., et al. (1989) · PubMed · Cited by 241
Vancomycin pharmacokinetics in normal and morbidly obese subjects
Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E., & Griffen, W. O. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.4.575 · Cited by 233
Drug Disposition in Obese Humans: An Update
Abernethy, D. R., & Greenblatt, D. J. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611030-00002 · Cited by 190
Delanaye, P., Radermecker, R. P., Rorive, M., Depas, G., & Krzesinski, J. M. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh983 · Cited by 190
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations
Liu, P., Müller, M., & Derendorf, H. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00024-9 · Cited by 186
Morbid obesity is an independent determinant of death among surgical critically ill patients*
Nasraway, S. A., Albert, M., Donnelly, A. M., Ruthazer, R., Shikora, S. A., & Saltzman, E. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000205758.18891.70 · Cited by 173
Vancomycin dosing in morbidly obese patients
Bauer, L. A., Black, D. J., & Lill, J. S. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050524 · Cited by 162
Population Pharmacokinetics of Linezolid in Patients Treated in a Compassionate-Use Program
Meagher, A. K., Forrest, A., Rayner, C. R., Birmingham, M. C., & Schentag, J. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.548-553.2003 · Cited by 154
Blood circulation in adipose tissue
Rosell, S., & Belfrage, E. (1979) · Physiological Reviews · doi:10.1152/physrev.1979.59.4.1078 · Cited by 151
Vancomycin Pharmacokinetics in a Patient Population
Ducharme, M. P., Slaughter, R. L., & Edwards, D. J. (1994) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199410000-00013 · Cited by 146
Dvorchik, B. H., & Damphousse, D. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269562 · Cited by 126
Glomerular volume and renal histology in obese and non-obese living kidney donors
Rea, D. J., Heimbach, J. K., Grande, J. P., Textor, S. C., Taler, S. J., Prieto, M., Larson, T. S., Cosío, B. G., & Stegall, M. D. (2006) · Kidney International · doi:10.1038/sj.ki.5001799 · Cited by 125
A Controlled Investigation of the Pharmacokinetics of Gentamicin and Tobramycin in Obese Subjects
Schwartz, S. N., Pazin, G. J., Lyon, J., et al. (1978) · The Journal of Infectious Diseases · doi:10.1093/infdis/138.4.499 · Cited by 125
Buerger, C., Plock, N., Dehghanyar, P., Joukhadar, C., & Kloft, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01468-05 · Cited by 122
Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac Surgery
Skhirtladze, K., Hutschala, D., Fleck, T., Thalhammer, F., Ehrlich, M. P., Vukovich, T., Müller, M., & Tschernko, E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1372-1375.2006 · Cited by 116
Vance‐Bryan, K., Guay, D. R. P., Gilliland, S. S., Rodvold, K. A., & Rotschafer, J. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.436 · Cited by 114
Intravenous ciprofloxacin disposition in obesity
Allard, S., Kinzig, M., Boivin, G., Sörgel, F., & Lebel, M. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.162 · Cited by 102
Chen, M., Nafziger, A. N., Drusano, G. L., Ma, L., & Bertino, J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1222-1227.2006 · Cited by 98
Björkman, S. E. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702320402080 · Cited by 97
Optimising Dosing Strategies of Antibacterials Utilising Pharmacodynamic Principles
DeRyke, C. A., Lee, S. Y., Kuti, J. L., & Nicolau, D. P. (2006) · Drugs · doi:10.2165/00003495-200666010-00001 · Cited by 95
Hollenstein, U., Brunner, M., Schmid, R., & Müller, M. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801555 · Cited by 94
Predictive Performance of Ten Equations for Estimating Creatinine Clearance in Cardiac Patients
Spinler, S. A., Nawarskas, J. J., Boyce, E. G., Connors, J. E., Charland, S. L., Goldfarb, S., & The Iohexol Cooperative Study Group (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.18122 · Cited by 93
Pharmacokinetics and Pharmacodynamics of Linezolid in Obese Patients with Cellulitis
Stein, G. E., Schooley, S. L., Peloquin, C. A., Kak, V., Havlichek, D. H., Citron, D. M., Tyrrell, K. L., & Goldstein, E. J. C. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e484 · Cited by 87
Daptomycin: A novel cyclic lipopeptide antimicrobial
Schriever, C. A., Fernández, C., Rodvold, K. A., & Danziger, L. H. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.11.1145 · Cited by 79
Obesity and Renal Hemodynamics
Bosma, R. J., Krikken, J. A., van der Heide, J. J. H., de Jong, P. E., & Navis, G. J. (2006) · KARGER eBooks · doi:10.1159/000095329 · Cited by 75
Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Langer, O., & Müller, M. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335379 · Cited by 68
Prophylactic cefazolin in gastric bypass surgery.
Pories, W. J., van Rij, A. M., Burlingham, B. T., et al. (1981) · PubMed · Cited by 62
Burkhardt, O., Brunner, M., Schmidt, S., Grant, M. B., Tang, Y., & Derendorf, H. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl284 · Cited by 58
Snider, R., Kruse, J. A., Bander, J. J., & Dunn, G. H. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb02892.x · Cited by 50
Wart, S. V., Phillips, L., Ludwig, E. A., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4766-4777.2004 · Cited by 48
Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients
Leader, W. G., Tsubaki, T., & Chandler, M. H. H. (1994) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/51.17.2125 · Cited by 46
Disposition of Cefotaxime and its Desacetyl Metabolite in Morbidly Obese Male and Female Subjects
Yost, R. L., & Derendorf, H. (1986) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198606000-00011 · Cited by 37
Therapeutic Drug Monitoring of Vancomycin in a Morbidly Obese Patient
Penzak, S. R., Gubbins, P. O., Rodvold, K. A., & Hickerson, S. L. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199806000-00005 · Cited by 34
Lovering, A. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.483 · Cited by 34
Fluconazole Serum Concentrations and Pharmacokinetics in an Obese Patient
Cohen, L. G., DiBiasio, A., Lisco, S. J., & Hurford, W. E. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03793.x · Cited by 33
Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits
Groll, A. H., Mickiene, D., Piscitelli, S. C., & Walsh, T. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.408-410.2000 · Cited by 30
Kampmann, J. P., Klein, H. C., Lumholtz, B., & Hansen, J. E. M. (1984) · Clinical Pharmacokinetics · doi:10.2165/00003088-198409020-00004 · Cited by 25
Intravenous Ciprofloxacin Dosing in a Morbidly Obese Patient
Caldwell, J. B., & Nilsen, A. K. (1994) · Annals of Pharmacotherapy · doi:10.1177/106002809402800622 · Cited by 25
Flucytosine Dosing in an Obese Patient With Extrameningeal Cryptococcal Infection
Gillum, J. G., Johnson, M., Lavoie, S., & Venitz, J. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb04361.x · Cited by 18
Cited by
Clinical practice guidelines for antimicrobial prophylaxis in surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120568 · Cited by 2,591
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery
Bratzler, D. W., Dellinger, E. P., Olsen, K. M., Perl, T. M., Auwaerter, P. G., Bolon, M. K., Fish, D. N., Napolitano, L. M., Sawyer, R. G., Slain, D., et al. (2013) · Surgical Infections · doi:10.1089/sur.2013.9999 · Cited by 1,197
Solomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Surgical Infections · doi:10.1089/sur.2009.9930 · Cited by 623
Metadata
- Authors
- Pai, M. P., & Bearden, D. T.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2007-08
- Volume
- 27
- Issue
- 8
- Pages
- 1081-1091
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1836909555
- Cited by
- 256
- References
- 53
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.